Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Current laboratory testing practices for mismatch repair deficiency and microsatellite instability testing: A survey-based review of current laboratory practices
Austin, Amy, Broaddus, Russell R. , Souers, Rhona J., Kane, Megan E , Kolhe, Ravindra , Miller, Dylan V. , Moncur, Joel T., Ramkissoon, Shakti, Trembath, Dimitri G. , Kolhe, Ravindra , Ramkissoon, Shakti, Tafe, Laura J. , Graham, Rondell P.

American Journal of Clinical Pathology | July 30, 2024 | Volume: 163 | Issue: 1 | Pages: 60-68

10.1093/ajcp/aqae094 | PMID 39078096 Get It

Abstract Objectives To describe mismatch repair (MMR) and microsatellite instability (MSI) testing practices in laboratories using the College of American Pathologists (CAP) MSI/MMR proficiency testing programs prior to the 2022 publication of the MSI/MMR practice guidelines copublished by CAP and the Association of Molecular Pathology (AMP). Methods Data from supplemental questionnaires provided with the 2020-B MSI/MMR programs to 542 laboratories across different practice settings were reviewed. Questionnaires contained 21 questions regarding the type of testing performed, specimen/tumor types used for testing, and clinical practices for checkpoint blockade therapy. Results Domestic laboratories test for MSI/MMR more often than international laboratories (P = .04) and academic hospitals/medical centers test more frequently than nonhospital sites/clinics (P = .03). The most commonly used testing modality is immunohistochemistry, followed by polymerase chain reaction, then next-generation sequencing. Most laboratories (72.6%; 347/478) reported awareness of the use of immune checkpoint inhibitor therapy for patients with high MSI or MMR-deficient results. Conclusions The results demonstrate the state of MMR and MSI testing in laboratories prior to the publication of the CAP/AMP best practice guidelines, highlighting differences between various laboratory types. The findings indicate the importance of consensus guidelines and provide a baseline for comparison after their implementation.
Engineered transcription activator-like effector dimer proteins confer DNA loop-dependent gene repression comparable to Lac repressor
Becker, Nicole A. , Peters, Justin P. , Lewis, Elizabeth B , Daby, Camden L. , Maher, L. James , Lewis, Elizabeth, Clark, Karl, III, Louis James Maher , Lewis, Elizabeth, Clark, Karl J.

Nucleic Acids Research | July 30, 2024 | Volume: 52 | Issue: 16 | Pages: 9996-10004

10.1093/nar/gkae656 | PMID 39077947 Get It

Abstract Natural prokaryotic gene repression systems often exploit DNA looping to increase the local concentration of gene repressor proteins at a regulated promoter via contributions from repressor proteins bound at distant sites. Using principles from the Escherichia coli lac operon we design analogous repression systems based on target sequence-programmable Transcription Activator-Like Effector dimer (TALED) proteins. Such engineered switches may be valuable for synthetic biology and therapeutic applications. Previous TALEDs with inducible non-covalent dimerization showed detectable, but limited, DNA loop-based repression due to the repressor protein dimerization equilibrium. Here, we show robust DNA loop-dependent bacterial promoter repression by covalent TALEDs and verify that DNA looping dramatically enhances promoter repression in E. coli. We characterize repression using a thermodynamic model that quantitates this favorable contribution of DNA looping. This analysis unequivocally and quantitatively demonstrates that optimized TALED proteins can drive loop-dependent promoter repression in E. coli comparable to the natural LacI repressor system. This work elucidates key design principles that set the stage for wide application of TALED-dependent DNA loop-based repression of target genes.
What Is the Role of Glucagon-Like Peptide 1 Signaling in the Nervous System and Its Potential Neuroprotective Effects?
Turcano, Pierpaolo , Savica, Rodolfo , Benarroch, Eduardo E. , Benarroch, Eduardo

Neurology | July 30, 2024 | Volume: 103 | Issue: 4 | Pages: No page available

10.1212/wnl.0000000000209781 | PMID 39079072 Get It

Clinicopathologic and Neuroimaging Correlations of Nonverbal Oral Apraxia in Patients With Neurodegenerative Disease
García-Guáqueta, Danna P. , Botha, Hugo , Utianski, Rene L. , Duffy, Joseph R. , Clark, Heather M. , Meade, Gabriela , Machulda, Mary M. , Dickson, Dennis W. , Pham, Nha Trang Thu, Whitwell, Jennifer L. , Josephs, Keith A. , Clark, Heather M , Meade, Gabriela , Utianski, Rene L , Dickson, Dennis W , Botha, Hugo , Duffy, Joseph R , Machulda, Mary M

Neurology | July 30, 2024 | Volume: 103 | Issue: 4 | Pages: No page available

10.1212/wnl.0000000000209717 | PMID 39079070 Get It

Incidence of Primary Progressive Apraxia of Speech and Primary Progressive Aphasia in Olmsted County, MN, 2011–2022
Turcano, Pierpaolo , Whitwell, Jennifer L. , Duffy, Joseph R. , Machulda, Mary M. , Josephs, Keith A. , Savica, Rodolfo , Mullan, Aidan, Josephs, Keith A , Savica, Rodolfo , Duffy, Joseph R , Machulda, Mary M , Mullan, Aidan F.

Neurology | July 30, 2024 | Volume: 103 | Issue: 4 | Pages: No page available

10.1212/wnl.0000000000209693 | PMID 39079073 Get It

Rectal Relief: Proton Therapy's Impact on Urgency and Frequency
Attia, Albert, Hoppe, Bradford S. , Hoppe, Bradford S , Saifi, Omran

Journal of Clinical Oncology | July 30, 2024 | Volume: 42 | Issue: 31 | Pages: 3762-3763

10.1200/jco.24.01162 | PMID 39079065 Get It

Reply to A. Sartore-Bianchi et al
Battaglin, Francesca , Ou, Fang‐Shu , Innocenti, Federico , Lenz, Heinz‐Josef , Ou, Fang-Shu

Journal of Clinical Oncology | July 30, 2024 | Volume: 42 | Issue: 30 | Pages: 3632-3634

10.1200/jco.24.01086 | PMID 39079060 Get It

Sex disparities in cardiac sarcoidosis patients undergoing implantable cardioverter‐defibrillator implantation
Ahmed, Raheel , Jamil, Yumna , Ramphul, Kamleshun , Mactaggart, Sebastian , Bilal, Maham , Shi, Rui , Azzu, Alessia , Memon, Rahat A , Sakthivel, Hemamalini, Khattar, Rajdeep , Wells, Athol U. , Baksi, John Arun, Wechalekar, Kshama , Sharma, Rakesh, Ahmed, Raheel , Dulay, Mansimran Singh , Okafor, Joseph , Kouranos, Vasileios , Chahal, C. Anwar A.

Pacing and Clinical Electrophysiology | July 30, 2024 | Volume: 47 | Issue: 10 | Pages: 1394-1403

10.1111/pace.15051 | PMID 39078380 Get It

AbstractIntroductionIn patients with cardiac sarcoidosis (CS), implantable cardioverter‐defibrillators (ICDs) are important for preventing sudden cardiac death. This study aimed to investigate sex disparities in CS patients undergoing ICD implantation.MethodsThe 2016–2020 National Inpatient Sample (NIS) database compared the characteristics and outcomes of males and females with CS receiving ICDs.ResultsAmong 760 CS patients who underwent inpatient ICD implantation, 66.4% were male. Males were younger (55.0 vs. 56.9 years, p < .01), had higher rates of diabetes (31.7% vs. 21.6%, p < .01) and chronic kidney disease (CKD) (16.8% vs. 7.8%, p < .01) but lower prevalence of atrial fibrillation (AF) (11.9% vs. 23.5%, p < .01), sick sinus syndrome (4.0% vs. 7.8%, p = .024), ventricular fibrillation (VF) (9.9% vs. 15.7%, p = .02), and black ancestry (31.9% vs. 58.0%, p < .01). Unadjusted major adverse cardiovascular events (MACE), defined as a composite of in‐hospital death, myocardial infarction (MI), and ischemic stroke, was higher in females (11.8% vs. 6.9%, p = .024), but when adjusted for age and tCharlson Comorbidity Index (CCI), females demonstrated significantly lower odds of experiencing MACE (aOR: 0.048, 95% CI: 0.006–0.395, p = .005). Incidence of acute kidney injury (AKI) post‐ICD was significantly lower in females (15.7% vs. 23.8%, p = .01) as was the adjusted odds (aOR: 0.282, 95% CI: 0.146–0.546, p < .01). There was comparable mean length of stay and hospital charges.ConclusionICD utilization in CS patients is more common among males, who have a higher prevalence of diabetes and CKD but a lower prevalence of AF, sick sinus syndrome, and VF. Adjusted MACE and AKI were significantly lower in females.
Improving Access to Patient-Focused, Decentralized Clinical Trials Requires Streamlined Regulatory Requirements: An ASCO Research Statement
Thota, Ramya , Hurley, Patricia A. , Miller, Therica M. , Bruinooge, Suanna S. , Lipset, Craig , Harvey, R. Donald , Black, Lora , Dinsdale, Amanda , Merrill, Janette K. , Pollastro, Teri , Prindiville, Sheila A. , Rizvi, Mujahid A., Sherwood, Shimere , Nowakowski, Grzegorz S. , Black, Lora J , Harvey, R Donald , Hurley, Patricia , Bruinooge, Suanna Steeby

Journal of Clinical Oncology | July 30, 2024 | Volume: 42 | Issue: 33 | Pages: 3986-3995

10.1200/jco.24.00961 | PMID 39079075 Get It

Strategies to bring clinical trials closer to patients gained momentum during the COVID-19 pandemic, enabling more participants to receive treatment and/or testing in their local communities. Incorporation of decentralized trial elements presents both opportunities and challenges, spanning regulatory, technical, and operational aspects. This ASCO research statement includes timely consensus-driven recommendations and a call for engagement of all research stakeholders. ASCO held multistakeholder meetings with leaders in oncology research and concluded that research-related regulatory and administrative requirements and burdens present critical barriers to decentralizing trials. One example is sponsor and contract research organization (CRO) use of US Food and Drug Administration (FDA)'s Statement of Investigator (Form 1572), which was found to exceed FDA's stated intent and used in conservative ways disproportionate to potential risks to participants and scientific integrity. As a result, research sites experience an avalanche of downstream administrative and regulatory activities that consume considerable resources. This statement recommends four key solutions to address such barriers and recalibrate regulatory and administrative expectations for decentralizing trials: (1) FDA should engage the research community in a public-private partnership to modernize standards and enable local access to trials; (2) sponsors and CROs should develop standards and protocols that accommodate flexible approaches, enable local participation, provide clarity around roles and requirements, and promote consistency; (3) research centers, networks, and sites should update policies and procedures to implement decentralized trial elements; and (4) research community should develop a streamlined, uniform mechanism to simplify regulatory data collection and documentation and use it consistently across trials. We can and must prioritize a concerted commitment to simplify and streamline regulatory requirements and practices to broaden access to and participation in cancer clinical trials.
Impact of Non-Alcoholic Fatty Liver Disease on Sepsis Inpatient Outcomes: A Nationwide Sample Analysis(2000-2019)
Lyu, Xiuhong , Liu, Bolun , Miskovsky, John, Gaitanis, Melissa , Promrat, Kittichai , Wu, Wen‐Chih , Liu, Bolun , Li, Yiting , Wang, Yichen

No container title available | July 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4673966/v1 Get It

Abstract Background It was reported that patients with Non-Alcoholic Fatty Liver Disease (NAFLD) were at increased risk of contracting severe infections requiring hospitalization which could end up with sepsis. However, data regarding the impact of comorbid NAFLD on the in-hospital outcomes of sepsis admission is scarce. Methods This nationwide retrospective observational study included 21,057,911 adult patients who were admitted into hospitals in the United States between 2000 and 2019 with a primary discharge diagnosis of sepsis. These patients were categorized according to the presence or absence of comorbid NAFLD. The twenty-year trend of nationwide NAFLD prevalence among sepsis inpatients was elucidated. Multivariate logistic regression analysis was used to analyze NAFLD's impact on in-hospital outcomes of sepsis. Results In the twenty-year study period, the prevalence of NALFD among sepsis inpatients trended up from 1.2% in 2000 to 4.2 % in 2019. While sepsis mortality had trended down, comorbid NAFLD in sepsis patients was consistently associated with a higher adjusted in-hospital all-cause mortality rate (adjusted odds ratio (OR), 1.45; 95% confidence interval (CI), 1.42-1.48), higher odds of developing septic shock, and multi-organ dysfunctions (including cardiovascular-, renal-, and hepatic dysfunction). They were more likely to be discharged to another acute hospital. The length of stay of sepsis patients with NAFLD who died in the hospital was significantly shorter than those without NAFLD. Conclusions Comorbid NAFLD is associated with higher in-hospital all-cause mortality and worse clinical outcomes in sepsis inpatients. Addressing this rising epidemic will be of paramount importance to improve sepsis in-hospital outcomes.